Signaling Pathway Activation After Exercise in Patients With Chronic Obstructive Pulmonary Disease (SIM)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Muscle weakness and atrophy are important consequences of chronic obstructive pulmonary disease (COPD). Although resistance exercises increase strength and muscle mass in patients with COPD, the response to training appears to be suboptimal in these individuals. A dysregulation in the signaling pathways involved in the regulation of muscle mass could play an important role in this phenomenon.
Hypothesis: Proteins involved in muscle mass regulation will be less activated in the quadriceps of patients with COPD following the acute bout of resistance training exercise compared to healthy age-matched controls.
| Condition | Intervention |
|---|---|
|
Chronic Obstructive Pulmonary Disease |
Other: exercise |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Signaling Pathway Activation in the Quadriceps of Patients With COPD After an Acute Bout of Resistance |
- Post-exercise signaling proteins phosphorylation level in the quadriceps of COPD patients and age-matched healthy controls [ Time Frame: 2 hours post-exercise ] [ Designated as safety issue: No ]Phosphorylation status of key proteins (Akt, p70, mTOR, p38, JNK, ERK) will be lesser modulated in the quadriceps of patients with COPD compare to healthy controls. The phosphorylated as well as the total protein levels will be measured by western blot. The data will be presented as arbitrary units and compared with values obtained in healthy age-matched healthy controls.
| Enrollment: | 21 |
| Study Start Date: | October 2009 |
| Study Completion Date: | April 2013 |
| Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
-
Other: exercise
Our objective is to investigate the impact of an acute bout of resistance training on key signaling pathways involved in the regulation of muscle mass in moderate to severe COPD (FEV1 under 60% of predicted). Key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured before after 72 contractions of the quadriceps. The exercise protocol was designed to match the actual exercise prescription model use in the context of pulmonary rehabilitation. A squat, leg press and leg extension will be done at 80% of max with one minute rest between sets. A biopsy of the quadriceps will be done before and after exercise in order to measure phosphorylated kinases, total protein content and mRNA expressions. All our patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition.
Eligibility| Ages Eligible for Study: | 50 Years to 75 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male
- COPD with an FEV1 of under 60% of predicted
- non-smoker
- Between 50 and 75 years old
Exclusion Criteria:
- All inflammatory disease (HIV, Cancer, renal and cardiac deficiency)
- Hormonal dysregulation
- Inferior limb pathology
- Neuromuscular pathology
- History of tabacco or alcool abuse
- Oxygen dependent
- Recent exacerbation (2 months) of the symptoms of COPD
Contacts and Locations| Canada, Quebec | |
| IUCPQ | |
| Quebec City, Quebec, Canada, G1V 4G5 | |
| Principal Investigator: | François Maltais, MD | Laval University |
More Information
No publications provided
| Responsible Party: | Bruno Lemire, Étudiant au doctorat, Laval University |
| ClinicalTrials.gov Identifier: | NCT01561625 History of Changes |
| Other Study ID Numbers: | SIM-COPD-20458 |
| Study First Received: | March 20, 2012 |
| Last Updated: | May 3, 2013 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Laval University:
|
COPD exercise training |
Additional relevant MeSH terms:
|
Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 16, 2013